RANI THERAPEUTICS HOLDINGS, INC.

RANI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-29.7M $-30.0M $-34.0M $-30.6M $-8.3M $-16.7M
Depreciation & Amortization $900.0K $1.0M $822.0K $548.0K $497.0K
Depreciation $900.0K $1.0M $800.0K $500.0K $500.0K $589.0K
Amortization
Stock-Based Compensation $11.8M $16.0M $19.0M $15.8M $22.6M
Net Cash from Operating Activities $-18.7M $-35.5M $-51.2M $-46.5M $-32.2M $-15.0M
Investing Activities
Capital Expenditures $88.0K $268.0K $1.2M $1.6M $506.0K $1.2M
Business Acquisitions
Net Cash from Investing Activities $-7.0M $19.8M $29.9M $-72.4M $-506.0K $-1.2M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $40.3M $13.6M $233.0K $29.0M $77.1M $72.7M
Net Change in Cash $14.6M $-2.1M $-21.1M $-89.9M $44.4M $56.5M
Free Cash Flow $-18.8M $-35.8M $-52.5M $-48.1M $-32.8M $-16.2M